secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2026-04-15T23:59:59+00:00
Accession:  0001437749-26-012381
Event type: debt
Sentiment:  positive
Materiality: 0.50
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharmaceuticals amends credit facility: rate reduced, interest-only extended to Nov 2026
--------------------------------------------------------------------------------

- Interest rate reduced to SOFR plus 6.55% (from 6.75%); SOFR floor lowered from 5.0% to 2.75%.
- Interest-only period extended to November 2026; optional principal payment in May 2026 or deferral.
- No fees paid to SWK for amendment; maturity unchanged at December 2027.
- Amendment conditions included consummation of Runway/SWK merger; representations and warranties reaffirmed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926012381/0001437749-26-012381-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926012381/eton20260409c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-012381

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer